Skip to main navigation
  • Home

  • Development Programs

  • VX15 Immuno-Oncology

  • VX15 Neurology

  • VX18 Neurology

  • VX15 Autoimmune

  • NKT Vaccine

  • NKT Vaccine

  • ActivMAb®

  • Vaccinia Display

  • Capabilities

  • Optimization

  • Target Identification

  • Publications

  • News & Publications

    • News

    • Publications

  • Careers

  • Corporate

    • Management

    • Partners

    • Contact

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Home

  • About

  • Corporate Overview

  • Management

  • Partners

  • Pipeline

  • Pepinemab
    Neurology

  • Pepinemab
    Immuno-Oncology

  • Research & Development Programs

  • Clinical Trials

  • Patients

  • Physicians & Researchers

  • News & Publications

    • News

    • Publications

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Careers

  • Contact Us

  • ActivMAb ®

    • Vaccinia

    • Antibody Discovery

    • Antigen Virus

    • Protein Optimization

    • Antigen Discovery

    • Antibody Optimization

    • ActivMAb ® Contact

Science in the service of medicine
  • About
    • Corporate Overview
    • Management
    • Partners
  • Pipeline
    • Pepinemab Neurology
    • Pepinemab Immuno-Oncology
    • Research & Development Programs
  • Clinical Trials
    • Patients
    • Physicians & Researchers
  • News & Publications
    • News
    • Publications
  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events
  • Presentations
  • Careers
  • Contact Us
  • ActivMAb ®
    • Vaccinia
    • Antibody Discovery
    • Antigen Virus
    • Protein Optimization
    • Antigen Discovery
    • Antibody Optimization
    • Contact Us

Investors

  • Investor Overview
  • News Releases
  • Events
  • Presentations
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Investor Services

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts
  • LinkedIn
  • Twitter

Filter by content type

  • (-) News (13)

Filter by form group

Filter by year

  • (-) 2020 (13)
News

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

May 13, 2020 - … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Annual Meeting … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
News

Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting

April 27, 2020 - … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Virtual Annual Meeting … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
News

Vaccinex Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 9, 2020 - … 03/09/20 Earnings On-track to report topline data from CLASSICAL-Lung and SIGNAL clinical trials this year Announces expansion … Clinical Updates: Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung clinical trial . Near topline data in the …
News

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 14, 2020 - … Earnings Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to … Accomplishments: Presented updated interim data from the CLASSICAL-Lung Phase 1b/2 study of the company’s lead product … . Pepinemab Clinical Updates: Non-Small Cell Lung Cancer - CLASSICAL-Lung Clinical Trial . The company’s ongoing …
News

Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 14, 2020 - … will be released by early October 2020 . Non-Small Cell Lung Cancer (NSCLC).   CLASSICAL-Lung clinical trial . The CLASSICAL-Lung study is evaluating pepinemab in combination …
News

Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs

March 31, 2020 - … Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial … and will provide further updates as warranted. CLASSICAL-Lung. The CLASSICAL-Lung study is evaluating pepinemab in combination …
News

Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium

February 6, 2020 - … in a Phase 1b/2 study in patients with non-small cell lung cancer (NSCLC). Interim results that we recently … the event.  Visit the website at www.vaccinex.com .  About CLASSICAL – Lung Vaccinex is currently evaluating its novel … , Darmstadt, Germany . The clinical trial, short-named “CLASSICAL – Lung”, is a multi-center, open-label study …
News

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 13, 2020 - … and loss of brain metabolic activity. Non-Small Cell Lung Cancer (NSCLC).   CLASSICAL-Lung C linical T rial . The recently completed CLASSICAL-Lung study evaluated pepinemab in combination with …
News

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

September 22, 2020 - … with avelumab checkpoint inhibitor in Non-Small Cell Lung Cancer . A new collaboration with Merck to test the … with currently active clinical trials in Non-Small Cell Lung Cancer , Huntington’s and Alzheimer’s disease and a … with avelumab checkpoint inhibitor in Non-Small Cell Lung Cancer . A new collaboration with Merck to test the …
News

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

June 9, 2020 - … clinical trials in Huntington’s disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . … clinical trials in Huntington’s disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . … clinical trials in Huntington’s disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . …

Pagination

  • Page 1
  • Next page ››

  • About
  • Pipeline
  • Clinical Trials
  • News
  • Careers
  • Contact
Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com
  • © 2023 Vaccinex. All rights reserved
  • |
  • Privacy Policy
  • |
  • Site by Minerva